Clinical trial
Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis…
NCT00390208 · Bay Area Retina Associates, Other · Completed
Key facts
| NCT number | NCT00390208 |
|---|---|
| Title | Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration |
| Official title | A Prospective Masked Pilot Study Comparing Group 1 Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Group 2 Monotherapy - Intravitreal Ranibizumab Alone. |
| Acronym | PDEX |
| Lead sponsor | Bay Area Retina Associates, Other |
| Collaborators | QLT Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Age Related Macular Degeneration |
| Intervention type | Drug |
| Interventions | ranibizumab, dexamethasone and verteporfin, Ranibizumab |
| Enrollment | 60 |
| Start date | Aug 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2009 |
| First posted | Oct 19, 2006 |
| Last update posted | May 27, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: